Serum and Urine Neutrophil Gelatinase-Associated Lipocalin Levels Measured at Admission Predict Progression to Chronic Kidney Disease in Sepsis-Associated Acute Kidney Injury Patients

Table 2

Baseline demographic and laboratory characteristics of patients.

Clinical characteristics and laboratory parameters	/median	, %
Ages (Min-Max)	(31 – 91)	N/A
Number of male (, %)	N/A	72 (59.5)
Hypertension (, %)	N/A	43 (35.5)
Diabetes mellitus (, %)	N/A	31 (25.6)
Blood urea (mmol/l)	11 (8.1–18)	N/A
Creatinine (μmol/l)	181 (152–254.5)
(i) Stage I	N/A	83 (68.6)
(ii) Stage II	N/A	28 (23.1)
(iii) Stage III	N/A	10 (8.3)
eGFR (ml/min/1.73m^2), median	27 (20–36.5)	N/A
Oliguria (n,%)	N/A	45 (37.2)
WBC (G/l), median	15.03 (12.83–19.59)	N/A
>12 G/l (, %)	N/A	102 (84.3)
<4 G/l (, %)	N/A	19 (15.7)
Neutrophil (G/l), median	12.05 (9.9–15.96)	N/A
PCT (ng/ml)	15.6 (11.2–31.2)	N/A
Na+ (mmol/l)		N/A
K+ (mmol/l)		N/A
MOF (, %)	N/A	84 (69.4)
Sepsis
(i) Bacteria positive (, %)	N/A	70 (57.9)
(ii) Bacterial negative (, %)	N/A	51 (42.1)
sNGAL (ng/ml)	415.17 (273.73–613.74)	N/A
uNGAL (ng/ml)	345.08 (138.92–734.59)	N/A
AKI to CKD (, %)	N/A	27 (22.3)

eGFR: estimated glomerular filtration rate; WBC: white blood cell; PCT: procalcitonin; MOF: multiple organ failure; sNGAL: serum neutrophil gelatinase-associated lipocalin; uNGAL: urine neutrophil gelatinase-associated lipocalin; AKI: acute kidney injury; CKD: chronic kidney disease; N/A: not available.